Elisabet E. Manasanch, M.D.

Peer-Reviewed Articles

1. Alomari M, Kunacheewa C, Manasanch EE. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. Leuk Lymphoma 64(2):1-12, 2023. e-Pub 2022. PMID: 36282671.
2. Chien KS, Peterson C, Young E, Chihara D, Manasanch EE, Ramdial J, Thompson PA. Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies. Blood Adv. e-Pub 2023. PMID: 36696472.
3. Ndacayisaba LJ, Rappard KE, Shishido SN, Setayesh SM, Tang G, Lin P, Matsumoto N, Hsu CJ, Nevarez R, Velasco CR, Naghdloo A, Yang E, Kelly K, Hicks J, Mason J, Orlowski RZ, Manasanch EE, Kuhn P. Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms. Int J Mol Sci 23(21), 2022. e-Pub 2022. PMID: 36362214.
4. Manasanch EE, Beksac M, Cavo M, Knauf W, Tsukada N, Tekle C, Zhao Z, Martin T. MM-086 Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S405-S406, 2022. PMID: 36164141.
5. Kalariya N, Ferreri C, Dillard C, Hawkins M, Manasanch E, Lee H, Weber D, Thomas S, Steiner R, Hosing C, Qazilbash M, Popat U, Orlowski R, Hildebrandt M, Patel K. CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel: A Single Center Study. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S446, 2022. PMID: 36164224.
6. Manasanch EE, Gertz MA. Response-adapted approach in newly diagnosed myeloma: when less is at least equal. Leuk Lymphoma:1-2. e-Pub 2022. PMID: 36093592.
7. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional experience. Am J Hematol 97(7):E276-E280, 2022. e-Pub 2022. PMID: 35472167.
8. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
9. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
10. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. Transplant Cell Ther. e-Pub 2022. PMID: 35605883.
11. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients. Clin Cancer Res 28(7):1277-1284, 2022. e-Pub 2022. PMID: 34992070.
12. Clay-Gilmour A, Chattopadhyay S, Hildebrandt MAT, Thomsen H, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Manasanch EE, Norman A, Kumar S, Rajkumar SV, Slager S, Försti A, Vachon CM, Hemminki K. Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. Blood Cancer J 12(4):60, 2022. e-Pub 2022. PMID: 35418122.
13. Ndacayisaba LJ, Rappard KE, Shishido SN, Ruiz Velasco C, Matsumoto N, Navarez R, Tang G, Lin P, Setayesh SM, Naghdloo A, Hsu CJ, Maney C, Symer D, Bethel K, Kelly K, Merchant A, Orlowski R, Hicks J, Mason J, Manasanch EE, Kuhn P. Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones. Curr Oncol 29(5):2954-2972, 2022. e-Pub 2022. PMID: 35621632.
14. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):1-12, 2022. e-Pub 2021. PMID: 34686083.
15. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
16. Kazandjian D, Hill E, Dew A, Morrison C, Roswarski J, Korde N, Emanuel M, Petrosyan A, Bhutani M, Calvo KR, Dulau-Florea A, Kwok M, Lee MJ, Lee S, Lindenberg L, Mailankody S, Manasanch E, Maric I, Mena E, Patel N, Tageja N, Trepel JB, Turkbey B, Wang HW, Wang W, Yuan C, Zhang Y, Braylan R, Choyke P, Stetler-Stevenson M, Steinberg SM, Figg WD, Roschewski M, Landgren O. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol 7(11):1678-1685, 2021. e-Pub 2021. PMID: 34529025.
17. Kunacheewa C, Manasanch EE. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. Expert Rev Hematol:1-11. e-Pub 2021. PMID: 34550841.
18. Lee HC, Feng L, Oriabure O, Graham V, Chen W, Badillo M, Lu R, Lee HJ, Jain P, Manasanch EE, Orlowski RZ, Wang ML. A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol 96(7):E243-E246, 2021. e-Pub 2021. PMID: 33811767.
19. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
20. Oben B, Froyen G, Maclachlan KH, Leongamornlert D, Abascal F, Zheng-Lin B, Yellapantula V, Derkach A, Geerdens E, Diamond BT, Arijs I, Maes B, Vanhees K, Hultcrantz M, Manasanch EE, Kazandjian D, Lesokhin A, Dogan A, Zhang Y, Mikulasova A, Walker B, Morgan G, Campbell PJ, Landgren O, Rummens JL, Bolli N, Maura F. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun 12(1):1861, 2021. e-Pub 2021. PMID: 33767199.
21. Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2020. PMID: 33781521.
22. Hao S, Lu X, Gong Z, Bassett RL, Hu S, Konoplev SN, Tang G, Li S, Xu J, Khanlari M, Lee HC, Manasanch EE, Weber DM, Orlowski RZ, Jeffrey Medeiros L, Lin P. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Mod Pathol 34(2):327-335, 2021. e-Pub 2020. PMID: 32908255.
23. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol 192(4):e115-e120, 2021. e-Pub 2021. PMID: 33486754.
24. Lipe DN, Elsayem A, Cruz-Carreras MT, Thomas J, Feliciano A, Ren J, Gaeta SM, Rajha E, Manasanch E, Kheder E, Brock P, Reyes-Gibby C. Characteristics of cancer patients with COVID-19 in a cancer hospital. Ann Palliat Med 10(2):1763-1771, 2021. e-Pub 2020. PMID: 33222454.
25. Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J 11(2):17, 2021. e-Pub 2021. PMID: 33563896.
26. Amini B, Nakache YN, Nardo L, Manasanch EE, Sun J, Lenchik L, Boutin RD. Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma. Skeletal Radiol 50(1):79-85, 2021. e-Pub 2020. PMID: 32621061.
27. Li Z, Liu H, He J, Wang Z, Yin Z, You G, Wang Z, Davis RE, Lin P, Bergsagel PL, Manasanch EE, Wong STC, Esnaola NF, Chang JC, Orlowski RZ, Yi Q, Yang J. Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. Cell Metab 33(1):78-93.e7, 2021. PMID: 33406405.
28. Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma 61(11):2763-2766, 2020. e-Pub 2020. PMID: 33167721.
29. Manasanch EE, Jain P, Chen W, Oriabure O, Badillo M, Feng L, Berkova Z, Orlowski RZ, Wang M. Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma. Am J Hematol 95(9):E232-E235, 2020. e-Pub 2020. PMID: 32390148.
30. Zou J, Jones RJ, Wang H, Kuiatse I, Shirazi F, Manasanch EE, Lee HC, Sullivan R, Fung L, Richard N, Erdman P, Torres E, Hecht D, Lam I, McElwee B, Chourasia AH, Chan KWH, Mercurio F, Stirling DI, Orlowski RZ. The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. J Mol Med (Berl) 98(8):1161-1173, 2020. e-Pub 2020. PMID: 32632752.
31. Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, Dabaja BS. New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica 105(7):e355-e357, 2020. e-Pub 2020. PMID: 31919088.
32. Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer 8(2), 2020. PMID: 32661116.
33. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2019. PMID: 31786242.
34. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ. Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica 105(5):e242-e245, 2020. e-Pub 2019. PMID: 31413094.
35. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk 20(5):e221-e238, 2020. e-Pub 2020. PMID: 32037287.
36. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2019. PMID: 31881283.
37. Kunacheewa C, Manasanch EE. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Best Pract Res Clin Haematol 33(1):101152, 2020. e-Pub 2020. PMID: 32139017.
38. Kunacheewa C, Lin P, Manasanch EE. Minimal residual disease in multiple myeloma 2019. Advances in Cell and Gene Therapy 3(Issue 1), 2020. e-Pub 2019.
39. Manasanch EE. What to do with minimal residual disease testing in myeloma. Hematology Am Soc Hematol Educ Program 2019(1):137-141, 2019. PMID: 31808833.
40. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of autologous transplantation in multiple myeloma patients with t(11;14): a propensity-score matched analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
41. Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J 9(10):80, 2019. e-Pub 2019. PMID: 31575851.
42. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk 19(9):560-569, 2019. e-Pub 2019. PMID: 31201134.
43. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
44. Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BS. Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. Clin Lymphoma Myeloma Leuk 19(8):e465-e469, 2019. e-Pub 2019. PMID: 31133526.
45. Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv 3(15):2400-2408, 2019. PMID: 31405950.
46. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 54(7):1089-1093, 2019. e-Pub 2018. PMID: 30446740.
47. Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma:1-8. e-Pub 2019. PMID: 31282244.
48. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
49. Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma 60(4):1-7, 2019. e-Pub 2018. PMID: 30227761.
50. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol 94(3):E72-E74, 2019. e-Pub 2018. PMID: 30548467.
51. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94(1):E2-E5, 2019. e-Pub 2018. PMID: 30300461.
52. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol 5(12):e628-e640, 2018. PMID: 30501870.
53. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma:1-11. e-Pub 2018. PMID: 30032678.
54. Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O. Host-related immunodeficiency in the development of multiple myeloma. Leuk Lymphoma 59(5):1-6, 2018. e-Pub 2017. PMID: 28792255.
55. Tageja N, Korde N, Kazandjian D, Panch S, Manasanch E, Bhutani M, Kwok M, Mailankody S, Yuan C, Stetler-Stevenson M, Leitman SF, Sportes C, Landgren O. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. Bone Marrow Transplant. e-Pub 2018. PMID: 29728700.
56. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):1-4, 2018. e-Pub 2017. PMID: 28673185.
57. Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu X. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol 30(10):1378-1386, 2017. e-Pub 2017. PMID: 28664940.
58. Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Adv 1(22):1911-1918, 2017. e-Pub 2017. PMID: 29296837.
59. Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
60. Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol 92(8):746-751, 2017. e-Pub 2017. PMID: 28383205.
61. Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 14(7):417-433, 2017. e-Pub 2017. PMID: 28117417.
62. Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu X. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol 30(6):843-853, 2017. e-Pub 2017. PMID: 28281554.
63. Manasanch EE, de Larrea CF, Zingone A, Steinberg SM, Kwok M, Tageja N, Bhutani M, Kazandjian D, Roschewski M, Wu P, Carter G, Zuchlinski D, Mulquin M, Lamping L, Costello R, Burton D, Gil LA, Figg WD, Maric I, Calvo KR, Yuan C, Stetler-Stevenson M, Korde N, Landgren O. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leuk Lymphoma 58(3):1-10, 2017. e-Pub 2016. PMID: 27687480.
64. Steiner RE, Manasanch EE. Carfilzomib boosted combination therapy for relapsed multiple myeloma. Onco Targets Ther 10:895-907, 2017. e-Pub 2017. PMID: 28243125.
65. Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
66. Manasanch EE. Recommend maintenance therapy with lenalidomide in multiple myeloma. Semin Oncol 43(6):712-713, 2016. e-Pub 2016. PMID: 28061994.
67. Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. e-Pub 2016. PMID: 27680710.
68. Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash M. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. e-Pub 2016. PMID: 27420405.
69. Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tageja N, Mailankody S, Roschewski M, Mulquin M, Carpenter A, Lamping E, Minter AR, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Usmani SZ, Choyke PL, Kurdziel K, Landgren O. Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: A prospective study using functional and morphologic imaging. Leuk Lymphoma 57(5):1-23, 2016. e-Pub 2016. PMID: 26690712.
70. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29(5):639-52, 2016. e-Pub 2016. PMID: 27132469.
71. Mian I, Milton D, Shah N, Nieto Y, Popat U, Kebriaei P, Parmar S, Oran B, Shah J, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash M, Bashir Q. Prolonged survival with longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation. Cancer 2016, 2016.
72. Alfaraj WA, Cachia D, Tummala S, Thomas SK, Manasanch EE. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia. Ann Hematol 95(2):347-348, 2016. e-Pub 2015. PMID: 26432713.
73. Cheah CY, Orlowski RZ, Manasanch EE, Oo TH. Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. Ann Hematol 94(9):1605-7, 2015. e-Pub 2015. PMID: 26044891.
74. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncol 1(6):746-54, 2015. e-Pub 2015. PMID: 26181891.
75. Manasanch EE, Salem DA, Yuan CM, Tageja N, Bhutani M, Kwok M, Kazandjian D, Carter G, Steinberg SM, Zuchlinski D, Mulquin M, Calvo K, Maric I, Roschewski M, Korde N, Braylan R, Landgren O, Stetler-Stevenson M. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leuk Lymphoma 56(5):1-24, 2015. e-Pub 2014. PMID: 25263319.
76. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant 50(5):668-72, 2015. e-Pub 2015. PMID: 25730192.
77. Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 20(4):400-10, 2015. e-Pub 2015. PMID: 25795635.
78. Manasanch EE, Korde N, Mailankody S, Tageja N, Bhutani M, Roschewski M, Landgren O. Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Haematologica 99(12):1769-71, 2014. PMID: 25472951.
79. Zingone A, Wang W, Corrigan-Cummins M, Wu SP, Plyler R, Korde N, Kwok M, Manasanch EE, Tageja N, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Roschewski M, Zhang Y, Roccaro AM, Ghobrial IM, Calvo KR, Landgren O. Altered cytokine and chemokine profiles in multiple myeloma and precursor disease. Cytokine 69(2):294-7, 2014. e-Pub 2014. PMID: 25043675.
80. Manasanch EE, Korde N, Zingone A, Tageja N, Fernandez de Larrea C, Bhutani M, Wu P, Roschewski M, Landgren O. The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma. Leuk Lymphoma 55(8):1707-14, 2014. e-Pub 2014. PMID: 24261677.
81. Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 99(6):e81-3, 2014. e-Pub 2014. PMID: 24658821.
82. Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 38(3):371-6, 2014. e-Pub 2013. PMID: 24462038.
83. Tageja N, Manasanch EE, Korde N, Kwok M, Mailankody S, Bhutani M, Roschewski M, Landgren O. Smoldering multiple myeloma: present position and potential promises. Eur J Haematol 92(1):1-12, 2014. e-Pub 2013. PMID: 24112232.
84. Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 54(10):2215-8, 2013. e-Pub 2013. PMID: 23311294.
85. Manasanch EE, Kristinsson SY, Landgren O. Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions. Clin Lymphoma Myeloma Leuk 13(2):194-7, 2013. e-Pub 2013. PMID: 23473950.
86. Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O. Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. Am J Hematol 88(2):89-92, 2013. e-Pub 2012. PMID: 23169485.
87. Manasanch EE, Grivas P, Walter O, Davaro R. Kidney actinomycosis, a rare diagnosis that can mimic renal cell carcinoma: a case report and review of the literature. Infectious Diseases in Clinical Practice 20(5):362-364, 2012.
88. Manasanch EE, Smith JK, Bodnari A, McKinney J, Gray C, McDade TP, Tseng JF. Tumor registry versus physician medical record review: a direct comparison of patients with pancreatic neuroendocrine tumors. J Oncol Pract 7(2):111-6, 2011. PMID: 21731519.
89. Villano JL, Collins CA,Manasanch EE, Ramaprasad C, van Besien K. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7(5):436-8, 2006. PMID: 16648049.
90. Szekely AM, Bleichert F, Nümann A, Van Komen S, Manasanch E, Ben Nasr A, Canaan A, Weissman SM. Werner protein protects nonproliferating cells from oxidative DNA damage. Mol Cell Biol 25(23):10492-506, 2005. PMID: 16287861.

Invited Articles

1. Surbhi S, Manasanch E. Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?. Hematology Am Soc Hematol Educ Program 2019(1):142-147, 2019. PMID: 31808853.
2. Manasanch EE, Orlowski RZ. Targeting the proteasome for cancer therapy. Nature Reviews, 2016.
3. Roschewski M, Manasanch EE, Wilson WH. Management of heavy chain diseases: the challenges of biologic heterogeneity. Oncology (Williston Park) 28(1):63-5, 2014. PMID: 24683720.
4. Manasanch EE, Kristinsson SY, Landgren O. Etiology of Waldenstrom macroglobulinemia: genetics factors and immune-related conditions. Clinical Lymphoma Myeloma Leukemia 13(2):194-7, 2013. e-Pub 2013. PMID: 23473950.

Editorials

1. Manasanch EE, Gertz MA. Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield. Leuk Lymphoma 61(8):1-3, 2020. PMID: 32543918.
2. Becnel M, Manasanch EE. Myeloma patients: genes increase risk for osteonecrosis of the jaw. Leuk Lymphoma 58(10):2271-2272, 2017. PMID: 28614996.
3. Manasanch EE. Pre-transplant bone marrow myeloma cells: less is better. Leuk Lymphoma 58(2):1-2, 2017. PMID: 27684409.
4. Manasanch EE. Myc is also the bad guy in myeloma. Leuk Lymphoma 57(11):2485-6, 2016. PMID: 27676421.
5. Manasanch EE. Recommend maintenance therapy with lenalidomide. Seminars in Oncology 10:1053, 10/09/2016, 2016.
6. Manasanch EE. Pre-transplant bone marrow myeloma cells: less is better. Leuk Lymphoma:1-2, 2016. PMID: 27684409.
7. Manasanch EE, Landgren O. Myeloma imaging: time to move on!. Leuk Lymphoma 57(7):1499-500, 2016. PMID: 27145898.
8. Manasanch EE. Thyroid hormones: turning up the heat in myeloma. Leuk Lymphoma 1-5(4):1-2, 2015. PMID: 25315079.

Abstracts

1. Becnel M, Ferreri CJ, Feng L, Richards TA, Horowitz SB, Patel N, Gombos DS, Razmandi A, Murga A, Seif S, Youssef G, Murphy K, Kaufman GP, Weber DM, Patel KK, Thomas SK, Manasanch EE, Orlowski RZ, Lee HC. Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma. J Clin Oncol 40, 2022 (suppl 16; )(abstr 8060), 2022.
2. Srour SA, Mehta RS, Shah N, Qazilbash MH, Im J, Bashir Q, Saini N, Nieto Y, Khouri IF, Daher M, Kebriaei P, Popat UR, Manasanch EE, Lee HC, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Rezvani K. Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). J Clin Oncol 40((suppl 16; abstr 8009)), 2022.
3. Mikkilineni L, Manasanch EE, Natrakul D, Brudno JN, Mann J, Goff SL, Yang JC, Lam N, Maric I, Stetler-Stevenson M, Wang H-W, Yuan CM, Lowe T, Stroncek DF, Highfill S, Patel R, Ganadan M, Rosenberg SA, Kochenderfer JN. Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. Blood 138(704), 2021.
4. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood 138(Session 731, No. 3941), 2021.
5. Shank BR, Primeaux B, Horowitz SB, Yeung EK, Lee IY, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Thomas SK. Daratumumab (Dara) and hyperfractionated cyclophosphamide (HyperCy)/dexamethasone (Dex) with and without carfilzomib (Car) for the treatment of relapsed/refractory multiple myeloma (RRMM). ASCO 38(15). e-Pub 2020.
6. Kazandjian D, Hill E, Morrison C, Dew A, Korde N, Mailankody S, Manasanch EE, Kwok ML, Bhutani M, Tageja N, Zhang Y, Carpenter A, Epstein M, Emanuel M, Lu C, Braylan RC, Calvo KR, Choyke P, Dulau-Florea A, Mena E, Lindenberg L, Maric I, Patel N, Stetler-Stevenson M, Wang H-W, Yuan CM, Steinberg SM, Figg WD, Roschewski M and Landgren O. Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. Blood 136(548), 2020.
7. Mikkilineni L, Manasanch EE, Vanasse D, Brudno JN, Mann J, Sherry R, Goff SL, Yang JC, Lam N, Maric I, Stetler-Stevenson M, Wang H-W, Yuan CM, Stroncek DF, Highfill SL, Fellowes V, Ganadan M, Patel R, Rosenberg SA and Kochenderfer JN. Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain. Blood 136(498), 2020.
8. Thomas SK, Cha S-C, Parshottam SR, Rao SS, Olsem JB, Crumpton BN, Szymura S, Wang Z, Anderson A, Feng L, Lee HC, Manasanch EE, Patel KK, Weber DM, Orlowski RZ, Neelapu SS and Kwak LW. A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM). Blood 136((2055)), 2020.
9. Becnel MR, Horowitz SB, Thomas SK, Iyer SP, Patel KK, Manasanch EE, Weber DM, Kaufman GP, Lee HC, and Orlowski RZ. Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. Blood 136((1371)), 2020.
10. Manasanch EE, Han G, Zhang Z, Dang M, Singh M, Khan M, Singh S, Lee HC, Patel KK, Kaufman GP, Amini B, Bashir Q, Srour SA Nieto Y, Qazilbash MH, Berkova Z, Pei Lin P, Berry D, Thomas SK, Weber DM, Futreal PA, Wang L, Orlowski RZ, and Neelapu SS. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma. Blood 136(Suppl 1), 2020.
11. Yeung EK, Primeaux BR, Horowitz SB, Shank BR, Lee IY, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Thomas SK. Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM). Blood 136((3216)), 2020.
12. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Hosing C, Patel KK, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE and Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood 136((2422)), 2020.
13. Afrough A, Alsfeld LC, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, and Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136((1512)), 2020.
14. Ramdial JL, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE, and Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood 136((1452)), 2020.
15. Afrough A, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE and Qazilbash MH. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136((2419)), 2020.
16. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing C, Ciurea SO, Daher M, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Kaufman GP, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin RE and Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood 136((2423)), 2020.
17. Singh RK, Jones RJ, Shirazi FM, Zou JM, Wang H, Lee HC, Manasanch EE, Kuiatse I, Pahl A and Orlowski RZ. The Anti-B-Cell Maturation Antigen (BCMA) Antibody-α-Amanitin Conjugate Hdp-101 Induces Immunogenic Cell Death and Immunologic Memory in Models of Multiple Myeloma. Blood 136(Suppl 1), 2020.
18. Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumpton BN, Stafford MD, Weber DM, and Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood 136((1394)), 2020.
19. Amini B, Nakache Y-P N, Nardo L, Manasanch EE, Lenchik L, Boutin RD. Psoas muscle uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma. RSNA, 2019.
20. Thomas SK, Cha S, Parshottam SR, Rao SS, Olsem JB, Crumpton BN, Feng L, Lee HC, Manasanch EE, Weber DM, Patel KK, Orlowski RZ, Neelapu SS, Kwak LW. Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom. J Clin Oncol (ASCO) 37(15):8050, 2019. e-Pub 2019.
21. Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Srour S, Bashir Q, Qazilbash MH, Weber DM, Neelapu SS, Orlowski RZ, Feng L, Lin P, Manasanch EE. Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM). J Clin Oncol (ASCO) 37(suppl; abstr 8024), 2019. e-Pub 2019.
22. Manasanch EE, Jagannath S, Lee HC, Patel KK, Graham C, Kaufman GP, Thomas SK, Iyer S, Mailankody S, Korde N, Amini B, Lin P, Berkova Z, Weber DM, Lei F, Lendvai N, Hildebrandt M, Neelapu SS, Orlowski RZ, Landgren O. A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). Blood 134(Suppl 1:3116), 2019.
23. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta RS, Kaufman GP, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis. Blood 134(Suppl 1:3198), 2019.
24. iKazandjian D, Korde N, Mailankody S, Zhang YO, Hsu JE, Hill ELI, Morrison C, Divakarla SN, Kwok ML, Manasanch EE , Bhutani M, , Tageja N, Galera PA, Dulau-Florea A, Salem DA, Gonzalez EST, Lindenberg L, Maric IR, Calvo KR, Braylan RC, Yuan C, Wilson WH, Choyke PE, Stetler-Stevenson M, Steinberg SM, Figg W, Roschewski M, and Landgren OL. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up. Blood Journal 132 Supply 1(1957), 2018.
25. Saini NY, Varma AN, Ma JUN, Milton DR, Patel ROM, Hasan OM, Bashir QAI, Nieto YAG, Mukherjee AKA, Delgado RUB, Rondon GAB, Popat UDA, Hosing CHI, Kebriaei PAR, Alousi AM, Ahmed SAI, Mehta RS, Ciurea SO, Khouri IF, Shpall EJ, Weber DM, Thomas SK, Lee HC, Manasanch EE , Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood Journal 132 Supply 1, 2018.
26. Varma AN, Saini NY, Sui DAW, Milton DR, Hasan OMA, Mukherjee AKA, Bashir QAI, Rondon GAB, Srour SA, Popat UDA, Hosing CHI, Nieto YAG, Kebriaei PAR, Alousi AMI, Mehta ROH, Khouri IF, Weber DM, Thomas SK, Manasanch EE , Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood Journal 132 Suppl 1, 2018.
27. Saini NY, Patel ROM, Varma AN, Bashir QAI, Delgado RUB, Popat UD, Hosing CHI, Nieto YAG, Kebriaei PAR, Alousi AM, Ahmed SAI, Mukherjee AKA, Mehta RS, Khouri IF, Ciurea SO, Shpall EJ, Hasan OM, Weber DM, Thomas SK, Lee HC, Manasanch EE , Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. Blood Journal 132 Suppl 1, 2018.
28. Santos DMCD, Sailba RM, Patel ROM, Bashir QAI, Hosing CHI, Kebriaei PAR, Khouri IF, Nieto YAG, Popat UD, Lee HC, Manasanch EE , Patel KK, Thomas SK, Weber, DM, Orlowski RZ, Champlin RE, Qazibash MH. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Blood Journal 132 Suppl 1, 2018.
29. Thomas SK, Shah JJ, Morphey AN, Lee HC, Manasanch EE , Patel KK, Miller CP, Phillips SU, Crumpton BN, Johnson RJ, Feng LEI, Iyer SW, Amini BEH, Weber DM, Orlowski RZ. Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood Journal 132 Suppl 1, 2018.
30. Becnel MR, Rubin ML, Nair RA, Manasanch EE , Lee HC, Patel KK, Iyer SW, Thomas SK, Weber DM, Orlowski RZ. Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens. Blood Journal 132 Suppl 1, 2018.
31. Saini NY, Patel R, Varma A, Bashir Q, Hasan O, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, and Patel KK. Clinical Autologous Transplantation: Results: Poster III. Blood 132((4606)), 2018.
32. Aboudalle I, Khan M, Feng L, Thomas SK, Manasanch EE,Patel K, Medeiros LJ, Mehta R, Bashir Q, Qazilbash M, Orlowski R, Weber D, Hu S, Hans Chulhee Lee;. Characteristics and outcomes of primary plasma cell leukemia in the era of novel agents: Single center experience. J Clin Oncol 36, 2018.
33. Tabchi S, Nair R, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed Sai, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng Lei, Manasanch EE . The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 36, 2018.
34. Hildebrandt MAT, Callender RA, Belachew AA, Classen C, Lee HC, Patel KK, Richards TA, Thomas SK, Weber DM, Orlowski RZ, Manasanch EE. Quality of life and cancer worry in a follow-up cohort of patients with asymptomatic monoclonal gammopathies. J Clin Oncol 36, 2018.
35. Saini NY, Patel ROM, Varma AN, Bashir QAI, Hasan OM, Delgado RUB, Rondon GAB, Mukherjee AKA, Popdat UD, Hosing CHI, Nieto YAG, Kebriaei PAR, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-Term Durable Responses after Autologous Stem Cel Transplantation in POEMS Syndrome. Blood 2018 ASH, 2018. e-Pub 2018.
36. Mathur R, Barnett BE, Hermanson D, He Jin, Zhang Z, Rengarajan S, Codde R, Wang X, Tan Y, Martin C, Smith J, Lee HC, Manasanch EE, Thomas SK, Patel KK, Weber DM, Davis RE, Orlowski RZ, Ostertag EM, Shedlock D, Yang Jing, Neelapu SS. B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient-Derived Multiple Myeloma Tumors. Blood Journal 130(Suppl 1):3068, 2017. e-Pub 2017.
37. Claussen CM, Chuang T, Chaudhry M, Lee HC, Patel KK, Bashir Q, Parmar S, Ahmed S, Mehta RS, Thomas SK, Richards TA, Nieto Y, Shpall EJ, Qazilbash MH, Amini B, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. Blood Journal 130(Suppl 1):4365, 2017. e-Pub 2017.
38. Manasanch EE, Mathur R, Lee HC, Weber DM, Patel KK, Thomas SK, Munoz SC, Partovi CM, Claussen CM, Lin Pei, Amini B, Wang L, John MC, Qing Yun, Lei Feng, Baladandayuthapani V, Davis RE, Neelapu SS, Orlowski RZ. Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma. Blood Journal 130(Suppl 1):3089, 2017. e-Pub 2017.
39. Manasanch EE, Yoon SS, Min CK, Kim JS, Shain KH, Hauptschein R, Choi JE, Lee KJ. Interim Results from the Phase 1a/1b Dose-Finding Study of CWP232291 (CWP291) in Relapsed or Refractory Myeloma (RRMM) Alone or in Combination with Lenalidomide and Dexamethasone. Blood Journal 130(Suppl 1):3091, 2017. e-Pub 2017.
40. Manasanch EE, Lee HC, Patel KK, Weber DM, Lee HJ, Thomas SK, Chen W, Oriabure O, Badillo M, Graham V, Lei F, McCarthy MS, Orlowski RZ, Wang M. A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma. Blood Journal 130(Suppl 1):3090, 2017. e-Pub 2017.
41. Chaudhry M, Steiner R, Claussen CM, Patel K, Lee HC, Weber DM, Thomas SK, Feng C, Kramer M, Amini B, Orlowski RZ, Feng L, Manasanch EE. Carfilzomib-Based Combination Regimens Are Highly Effective Frontline Therapies for Multiple Myeloma and Waldenström's Macroglobulinemia. Blood Journal 130(Suppl 1):1880, 2017. e-Pub 2017.
42. Thomas SK, Shah JJ, Lee HC, Manasanch EE, Weber DM, Patel KK, Feng L, Amini B, Morphey A, Crumpton B, Phillips S, Miller C, Gonzalez M, Orlowski RZ. Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood Journal 130(Suppl 1):840, 2017. e-Pub 2017.
43. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EE, Thomas SK, Weber DM, Munoz SC, Morphey A, Bashir Q, Qazilbash MH, Orlowski RZ. Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood Journal 130(Suppl 1):437, 2017. e-Pub 2017.
44. Manasanch EE, Claussen CM, Dong W, Lee HC, Thomas SK, Patel KK, Reed VK, Dabaja BS, Milgrom S, Pinnix CC, Parmar S, Bashir Q, Qazilbash MH, Amini B, Raymond A, Orlowski RZ, Feng L, Weber DM. A Clinical Model of Progression to Multiple Myeloma in Solitary Plasmacytoma. Blood Journal 130(Suppl 1):5367, 2017. e-Pub 2017.
45. Qazilbash MH, Bashir Q, Thall PF, Milton DR, Shah N, Patel KK, Andersson BS, Nieto Y, Kebriaei P, Valdez BC, Kawedia J, Parmar S, Delgado R, Ahmed S, Hosing C, Popat U , Shpall EJ, Weber DM, Thomas SK, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. Blood Journal 130(Suppl 1):399, 2017. e-Pub 2017.
46. Mathur R, Zhang Z, He J, Galetto R, Gouble A, Sotinel IC, Filipe S, Gariboldi A, Veeramachaneni T, Manasanch EE, Thomas SK, Lee HC, Patel KK, Weber DM, Davis RE, Orlowski RJ, Smith J, Yang J, Neelapu SS. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma. Blood Journal 130(Suppl 1):502, 2017. e-Pub 2017.
47. Yoon S-S, Manasanch E, Min CK, Kim JS, Hauptschein RS, Choi J, Chun JK. Novel phase 1a/1b dose-finding study design of CWP232291 (CWP291) in relapsed or refractory myeloma (MM). Blood 35(suppl; abstr TPS8058), 2017.
48. Bashir Q, Shazly ME, Milton DR, Patel K, Shah N, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash M. Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. Blood 2016 128(22):3453, 2016. e-Pub 2016.
49. Kazandjian D, Korde NS, Roschewski M, Mailankody S, Morrison C, Manasanch EE, Kwok ML, Tageja N, Bhutani M, Zingone A, Costello R, Zhang Y, Mulguin M, Lamping L, Carpenter A, Roberson B, Maric I, Calvo KR, Braylan RC, Yuan, CM, Stetler-Stevenson M, Arthur DC, Lindenberg L, Kurdziel KA, Choyke P, Steinberg SM, Figg W, Wilson WH, Landgren O. Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of Phase 2 Study. Blood 2016 128(22):4527, 2016. e-Pub 2016.
50. Claussen CM, Lee H, Shah JJ, Richards T, Shah N, Patel K, Bashir Q, Parmar S, Thomas S, Nieto Y, Qazilbash MH, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood 2016 128(22):5628, 2016. e-Pub 2016.
51. Yoon SS, Min CK, Kim JS, Manasanch EE, Hauptschein R, Choi J, Lee KJ. Ongoing Phase 1a/1b Dose-Finding Study of CWP232291 (CWP291) in Relapsed or Refractory Multiple Myeloma (MM). Blood 2016 128(22):4501, 2016. e-Pub 2016.
52. Veltri LW, Milton DR, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma. Blood 2016 128(22):4626, 2016. e-Pub 2016.
53. Castillo JJ, Jurczyszyn AJ, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine J, Hájek R, Hungria v, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Nahi H, Niesvizky R, Paba-Prada CE, Pika T, Pour L, Reagan JL, Richardson PG, Shah JJ, Spicka I, Vij R, Waszczuk A, Gertz MA. IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood 2016 128(22):3276, 2016. e-Pub 2016.
54. Kazandjian D, Korde NS, Roschewski M, Mailankody S, Morrison C, Manasanch EE, Kwok ML, Tageja N, Bhutani M, Zingone A, Costello R, Zhang Y, Mulguin M, Lamping L, Carpenter A, Roberson B, Maric I, Calvo KR, Braylan RC, Yuan, CM, Stetler-Stevenson M, Arthur DC, Lindenberg L, Kurdziel KA, Choyke P, Steinberg SM, Figg W, Wilson WH, Landgren O. Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study. Blood 2016 128(22):3339, 2016. e-Pub 2016.
55. Mohyuddin GR, Faisal MS, Shah N, Bashir Q, Hosing C, Patel K, Popat UR, Parmar S, Rondon G, Delgado R, Weber DM, Shah JJ, Thomas S, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Blood 2016 128(22):4613, 2016. e-Pub 2016.
56. Manasanch EE, Fernandez de Larrea C, Zingone A, Steinberg SM, Kwok M, Tageja N, Bhutani M, Kazandjian D, Roschewski M, Wu P, Carter G, Zuchlinski D, Mulquin M, Lamping L, Costello R, Burton D, Gil L, Figg D, Maric I, Calvo K, Yuan C, Stetler-Stevenson M, Korde N, Landgren O. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia and Lymphoma:1-10, 2016. e-Pub 2016. PMID: 27687480.
57. Mathur R, Manasanch E b|, Shah J, Weber D, Thomas S, Lee HC, Davis E, Orlowski R, Neelapu SS. Immune escape mechanisms associated with early progression from smoldering multiple myeloma to symptomatic multiple myeloma. 2nd Annual Immuno-therapy in Myeloma Scientific Workshop, Boston, MA, 2016.
58. Hu B, Sasaki K, Bashir Q, Shah N, Patel KK, Popat UR, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen JL, Shah JJ, Manasanch EEb||, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH,. Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM). 2016 ASCO Annual Meeting, 2016.
59. Mailankody S, Korde N, Roschewski MJ, Christofferson A, Boateng M, Zhang Y, Manasanch EEb||, Kazandjian DG, Kwok M, Bhutani M, Tageja N, Zingone A, Costello R, Lamy L, Hultcrantz M, Papaemmanuil E, Stetler-Stevenson M, Figg WD, Keats JJ, Landgren O,. Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients. 2016 ASCO Annual Meeting, 2016.
60. Shah J, Fend L, Manasanch Eb||, Weber D, Thomas S, Turturro F, Shah N, Popat UR, Nieto Y, Bashir Q, Munoz S, Landry A, Mendoza K, Champlin RE, Qazilbash MH, Orlowski RZ. Impact of Induction Therapy on Outcomes in Newly diagnosed Myeloma Patients who received upfront Autologous Stem Cell Transplant and Maintenance Lenalidomide. American Society of Hematology Meeting, 2015.
61. Shah J, Feng L, Thomas S, Weber D, Wang M, Manasanch EEb||, Mendoza K, Orlowski RZ. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood 126(23), 2015.
62. Claussen CM, Chuang T, Shah J, Lee H, Shah N, Patel KK, Bashir Q, Parmar S, Thomas S, Qazilbash M, Davis RE, Neelapu SS, Weber D, Orlowski RZ, Feng L, Manasanch Eb||. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood 126(23), 2015. e-Pub 2015.
63. Shah JJ, Feng L, Manasanch EEb||, Weber D, Thomas SK, Turturro F, Shah N, Popat UR, Nieto Y, Bashir Q, Munoz SC, Landry A, Mendoza K, Champlin RE, Qazilbash MH, Orlowski RZ. Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomid/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 126(23), 2015.
64. Shah JJ, Feng L, Weber D, Thomas SK, Wang M, Turturro F, Qazilbash MH, Shah N, Bashir Q, Popat UR, Manasanch EEb||, Munoz SC, Landry A, Mendoza K, Nieto Y, Champlin RE, Orlowski RZ. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 126(23):3155-3155, 2015. e-Pub 2015.
65. Manasanch EE, Claussen C, Dong W, Shah J, Lee H, Thomas S, Reed VK, Dabaja BS, Milgrom S, Pinnix CC, Parmar S, Shah N, Patel K, Bashir Q, Qazilbash M, Orlowski RZ, Feng L, Weber D. Clinical characteristics, outcomes and predictors of progression to multiple myeloma (MM) in 61 patients with solitary plasmacytoma. International Myeloma Workshop. Rome 15:e181-e182, 2015. e-Pub 2015.
66. Shah JJ, Feng L, Manasanch EE, Weber DM, Thomas SK, Turturro F, Alexanian R, Nina Shah N, Popat UR, Qaiser YN, Bashir Q, Qazilbash MH, Champlin RE, Orlowski RZ. Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 124(21):33, 2014.
67. Korde N, Mailankody S, Roschewski M, Faham M, Kotwaliwale C, Moorhead M, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Costello R, Zhang Y, Zingone A, Burton D, Mulquin M, Carpenter A, Zuchlinski D, Lamping E, Carter G, Morrison C, Kurdziel K, Lindenberg M, Kurlander R, Maric I, Calvo KR, Braylan RC, Yuan C, Stetler-Stevenson M, Arthur DC, Steinberg SM, Figg WD, Choyke PLandgren O. Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities. Blood 124(21), 2014.
68. Landgren O, Roschewski M, Mailankody S, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Zingone A, Costello R, Burton D, Zhang Y, Wu P, Carter G, Mulquin M, Zuchlinski D, Carpenter A, Gounden V, Morrison C, Maric I, Calvo KR, Braylan RC, MD4, Yuan C, Stetler-Stevenson M, Arthur DC, Lindenberg L, Karen K, Choyke P, Steinberg SM, Figg WD, Korde N. Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study. Blood 124:4746, 2014.
69. Bock FM, Lu G, Shah N, Bashir Q, Patel KK, Popat UR, Hosing CM, S, Korbling,M Delgado R, Rondon G, Orlowski RZ, Shah JJ,Manasanch EE, Champlin RE, Qazilbash MH. Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation. Blood 124(21):2521, 2014.
70. Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EEb||, Tageja N, Mailankody S, Roschewski MJ, Mulquin M, Lamping E, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Choyke PL, Kurdziel KA, Landgren O. Focal bone marrow processes and early bone lesions in patients with multiple myeloma (MM) precursor diseases: A prospective study using molecular imaging. American Society of Clinical Oncology 32(5s), 2014.
71. Dosani T, Korde N, Manasanch EE, Tageja N, Mailankody S, Roschewski MJ, Kwok M, Kazandjian DG, Landgren O, Maric I. Large granular lymphocyte (LGL) subsets in smoldering multiple myeloma (SMM): Immunophenotypic profiles that predict progression to multiple myeloma (MM). American Society of Clinical Oncology 32(5s), 2014.
72. Manasanch EE, Korde N, Yuan C, Kwok M, Tageja N, Bhutani M, Flanders AW, Zingone A, Costello R, Tembhare P, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Steinberg SM, Roschewski MJ, Landgren O, Braylan R, Stetler-Stevenson M. Biological variations of plasma cells in the bone marrow of smoldering multiple myeloma (SMM) and multiple myeloma (MM) patients: multiple biopsies in the same patient. Journal of Clinical Oncololgy 31(15), 2013.
73. Tageja N, Wang W, Plyler R, Corrigan-Cummins M, Korde N, Manasanch EE. Altered cytokine profiles in multiple myeloma (MM) and precursor disease: Predictors of progression and potential targets for treatment. Journal of Clinical Oncology 31(15), 2013.
74. Manasanch EE, Fernandez C, Zingone A, Korde N, Tageja N, Bhutani M, Kazandjian D, Wu P, Costello R, Burton D, Carter G, Zuchlinski D, Mulquin M, Maric I, Calvo KR, Yuan C, Stetler-Stevenson M, Roschewski M, Landgren O. Enzymatic activity of circulating plasma proteasomes (cProt) in newly diagnosed multiple myeloma (NDMM) patients undergoing treatment with carfilzomib, revlimid and dexamethasone (CRd). Blood 122(21), 2013.
75. Mailankody S, Korde N, Faham M, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Weng L, Moorhead M, Costello R, Zhang Y, Zingone A, Burton D, Wu P, Mulquin M, Zuchlinski D, Kurlander R, Maric I, Calvo KR, Braylan RC, Yuan C, Stetler-Stevenson M, Arthur DC, Roschewski M, Landgren O. Molecular sequencing for minimal residual disease (MRD) detection in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Blood 122(21), 2013.
76. Landgren C, Zingone A, Kwok M, Manasanch EE. Clinical and correlative pilot study of carfilzomib, lenalidomide and dexamethasone followed by lenalidomide extended dosing (CRD-R) in high risk smoldering multiple myeloma. IMWG Khyoto, Japan, 2013.
77. Bhutani M, Korde N, Kwok M, Manasanch EE. Normalization of serum free light chain (sFLC) ratio as a biomarker for negative minimal residual disease (MRD) in patients treated with carfilzomib, lenalidomide and dexamethasone followed by lenalidomide maintenance (CRd-R) for newly diagnosed myeloma. Blood 122(21), 2013.
78. Fernández de Larrea C, Zingone A, MD, Manasanch EE, Korde N, Wu P, Costello R, Zuchlinski D, Mulquin M, Burton D,Maric I, Calvo KR, Stetler-Stevenson M, Yuan C, Roschewski M, Landgren O. Plasma circulating proteasomes as biomarkers along natural history of asymptomatic monoclonal gammopathies. Blood 122(21), 2013.
79. Manasanch EE, Jordan E, Korde N. Plasma cell proliferation fraction and the risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM). EHA, 2013.
80. Korde N, Zingone A, Kwok M, Manasanch EE. Combination CRd therapy followed by extended LEN dosing in newly diagnosed MM patients shows deep response rates corroborated by MRD assays and tolerable side effects. EHA, 2013.
81. Korde N, Espana K, Manasanch EE. Uninvolved Heavy-light-chain Pair Suppression (UHLCPs) in Smoldering Myeloma: New Insights. IMWG Kyoto, Japan, 2013.
82. Landgren O, Mailankody S, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Zingone A, Costello R, Burton D, Zhang Y, Wu P, Carter G,Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan RC,Yuan C,Stetler-Stevenson M, Arthur DC, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Roschewski M, Korde N. Clinical and Correlative (Phase II) Pilot Study – Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (Dex) in High Risk Smoldering Multiple Myeloma (“Early Myeloma”). Blood 122(21), 2013.
83. Korde N, Zingone A, Kwok M, Manasanch EE, Costello R, Zuchlinski D, Mulquin M, Maric I, Calvo KR, Braylan RC, Yuan C, Tembhare PR, Stetler-Stevenson M, Arthur DC, Raffeld M, Xi L, Choyke P, Kurdziel K, Lindenberg, L Steinberg SM, Roschewski M, Landgren O. Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients. Blood 120(21), 2012.
84. Kwok ML, Korde N, Manasanch EE, Flanders AW, Maric I, Calvo KR, Zingone A, Costello R, Cordaro D, Sato A, Mulquin M, Zuchlinski D, Roschewski M, Landgren O. Altered plasma cell characteristics in smoldering myeloma and MGUS patients preceding immune-related conditions. Blood 120(21), 2012.
85. Korde N, Liu QY, Kwok M, Manasanch EE, Simakova O, Mailankody S, Roschewski M, Zingone A, Costello R, Zuchlinski D, Mulquin M, Calvo KR, Braylan RC, Maric I, Landgren O. Early myelodysplastic changes present in substantial proportion of monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) patients. Blood 120(21), 2012.
86. Tembhare PR, Yuan C, Korde N, Manasanch EE, Kwok M, Roschewski M, Maric I, Calvo KR, Mulquin M, Zuchlinski D, Landgren O, Stetler-Stevenson MA. Peripheral blood involvement with minimal disease is common in multiple myeloma but not in smoldering myeloma. Blood 120(21), 2012.
87. Kwok M, Korde N, Manasanch EE, Bhutani M, Maric I, Calvo KR, Zingone A, Costello R, Cherry BM, Yancey MA, Mulquin M, Roschewski MJ, Landgren O. Role of immune-related conditions in smoldering myeloma and MGUS. Journal of Clinical Oncology 30(15), 2012.
88. Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Yancey MA, Mulquin M, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O. A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM). Journal of Clinical Oncology 30(15), 2012.
89. Korde N, Zingone A, Kwok M, Manasanch EE, Bhutani M, Costello R, Yancey MA, Mulquin M, Calvo KR, Maric I, Tembhare P, Yuan C, Stetler-Stevenson M, Arthur DC, Choyke PL, Kurdziel KA, Steinberg SM, Raffeld M, Roschewski MJ, Landgre O. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. Jounal of Clinical Oncology 30(15), 2012.
90. Korde N, Zingone A, Kwok M, Manasanch EE, Costello R, Zuchlinski D, Mulquin M, Maric I, Calvo KR, Braylan RC, Yuan C, Tembhare PR, Stetler-Stevenson M, Arthur DC, Raffeld M, Xi L, Choyke P, Kurdziel K, Lindenberg L, Steinberg SM, Roschewski M, Landgren O. Phase II clinical and correlative study of carfilzomib, lenalidomide and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. J Clin Oncol 30(15), 2012.
91. Manasanch EE, Wilkerson J, Xiu L, Zhuang S, Bates S, Stein W, Fojo AT. Assessment of Tumor Growth (g) and Regression (d) Rate Constants in Patients with Multiple Myeloma (MM) Shows That the Superiority of Bortezomib with Liposomal Doxorubicin (PLD+B) Over Bortezomib Alone (B) Is a Result of Reduced Growth of Refractory Tumor Cells and Not of Higher Regression Rates, and Provides An Earlier Efficacy Endpoint That Allows for Comparison Across Trials. Blood 118(21):5113, 2011.
92. 78. Banerjee R, Shah N, Brassil K, Jackson L, b|Manasanch E</b>. Patient-Reported Outcomes of Individuals Receiving Isatuximab for Relapsed/Refractory Multiple Myeloma in a Digital Health Pilot Study: A Real-World Trial in Progress. MASCC/ISOO 2021 Annual Meeting.

Book Chapters

1. Lee HC, Patel K, Kongtim P, Parmar S, Lin P, Qazilbash MH, Thomas S, Manasanch EE. Multiple Myeloma and Other Plasma Cell Dyscrasias. In: MD Anderson Manual for Medical Oncology. 3rd. McGraw Hill, 2015.
2. Manasanch EE, Tageja N, Landgren O. Multiple Myeloma. In: Bethesda Handbook of Clinical Hematology. 3rd, 2013.
3. Manasanch EE, Lozier J. Venous Thromboembolism. In: Bethesda Handbook of Clinical Hematology. 3rd, 2013.

Letters to the Editor

1. Manasanch EE, Braylan R, Stetler-Stevenson M, Yuan C, Gounden V, Korde N, Tageja N, Bhutani M, Calvo K, Maric I, Roschewski M, Staudt LM, Landgren O. Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leuk Lymphoma 55: 1402-3, 2014.
2. Manasanch EE, Freeman AF, Pittaluga S, Costello R, Holland SM, Landgren O. Serum free light chains as predictors of lymphomagenesis in patients with autosomal dominant hyper-immunoglobulin E syndrome (Job's syndrome). Leuk Lymphoma 54: 1316-7, 2013.